SUO 2023
Advertisement
Similar to results from the intention-to-treat population, pembrolizumab was favored for its benefit of prolonging DFS.
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
An analysis compared the outcomes of patients with mRCC who underwent cytoreductive nephrectomy and first-line TKI or IO.
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
A poster reported on AEs occurring after Lu-PSMA treatment, as well as variables associated with ER visits.
Recent data suggest good quality of life outcomes for patients with muscle-invasive bladder cancer after trimodality therapy.
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
The meeting covers a range of topics, including prostate cancer, kidney cancer, and bladder cancer, as well as penile cancer.
The SUO meeting pays special attention to patients who responded well to NAC, the BCG shortage, trimodal therapy, and more.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.